Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjug
Data demonstrate higher internalization in cMET positive (cMET+) tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of non-small cell lung cancer (NSCLC), as compared to other cMET-targeting ADCsData establish preclinical proof of concept for MYTX-011...
Source: pharmiweb.com